Across TCGA pan-cancer cohorts, SIGLEC15 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated SIGLEC15 data layer compared with 1 for mutation status.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SIGLEC15 RNA is associated with better overall survival. In most high-consensus cancer types, elevated SIGLEC15 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.
BLCA, UCEC, and DLBC are the cancer types where SIGLEC15 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.